BLA 208471 · Sanofi-Aventis US
Adlyxin
Lixisenatide · Subcutaneous
NovelLast checked: Nov 20, 2026Latest source record: Mar 12, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2016
Jul 27, 2016
Approved uses
2
Original approval plus efficacy supplements
Registered trials
69
33 Phase 3, 2 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jul 30, 2021 Supplement 4 · Efficacy LetterLabel
- Jul 27, 2016 Original approval · Type 1 - New Molecular Entity NovelReviewLetterLabel
2 products under this application
- ADLYXIN · LIXISENATIDE 0.15MG/3ML (0.05MG/ML) · SOLUTION, SUBCUTANEOUS · Prescription
- ADLYXIN · LIXISENATIDE 0.3MG/3ML (0.1MG/ML) · SOLUTION, SUBCUTANEOUS · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Lixisenatide" as an intervention, any sponsor and status, largest first.
- Evaluation of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Acute Coronary Syndrome During Treatment With AVE0010 (Lixisenatide)Pivotal-lookingCompleted
SanofiSanofi (SNY)
NCT01147250 · 6,068 participants · Start Jun 2010 · Primary completion Feb 2015
Drug: Lixisenatide (AVE0010); Placebo · For: Acute Coronary Syndrome
Sites: Birmingham, Alabama; Foley, Alabama; Mobile, Alabama · 829 sites in all
- Efficacy and Safety of iGlarLixi Versus Standard of Care in a Real-world Adult China Population With Uncontrolled Type 2 Diabetes on Oral AgentsPivotal-lookingRecruiting
Shanghai Zhongshan HospitalAcademic, hospital or other
NCT07307235 · 1,316 participants (planned) · Start Dec 13, 2025 · Primary completion Jun 30, 2027
Drug: iGlarLixi (insulin glargine/lixisenatide); standard of care (basal insulin or premixed insulin, excluding any GLP-1 receptor agonist-containing drugs) · For: Type 2 Diabetes
Sites: Hefei, China; Huizhou, China; Shenzhen, China · 24 sites in all
- Efficacy and Safety of Insulin Glargine/ Lixisenatide Fixed Ratio Combination Compared to Insulin Glargine Alone and Lixisenatide Alone on Top of Metformin in Patients With T2DMPivotal-lookingCompleted
SanofiSanofi (SNY)
NCT02058147 · 1,170 participants · Start Feb 2014 · Primary completion Jun 2015
Drug: Insulin glargine/lixisenatide Fixed Ratio Combination; Insulin glargine (HOE901) and 2 more · For: Type 2 Diabetes
Sites: Phoenix, Arizona; Tempe, Arizona; Little Rock, Arkansas · 273 sites in all
Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic DisordersAcademic, hospital or other
NCT06449235 · 938 participants (planned) · Start Sep 2024 · Primary completion Apr 2025
Drug: Omarigliptin; Sulphonylureas and 7 more · For: Type2diabetes
Sites: Dhaka, Bangladesh
- Efficacy and Safety of Lixisenatide Versus Insulin Glulisine on Top of Insulin Glargine With or Without Metformin in Type 2 Diabetic PatientsPivotal-lookingCompleted
SanofiSanofi (SNY)
NCT01768559 · 894 participants · Start Jan 2013 · Primary completion Dec 2014
Drug: Lixisenatide (AVE0010); Insulin glulisine QD and 3 more · For: Type 2 Diabetes
Sites: Sun City, Arizona; Tempe, Arizona; Little Rock, Arkansas · 199 sites in all
- Evaluation of Insulin Glargine/Lixisenatide Fixed Ratio Combination in Patients With Type 2 Diabetes Insufficiently Controlled With Oral Antidiabetic Drug(s)Pivotal-lookingCompleted
SanofiSanofi (SNY)
NCT03798054 · 878 participants · Start Feb 15, 2019 · Primary completion Mar 1, 2021
Drug: Insulin glargine/Lixisenatide (HOE901/AVE0010); Insulin glargine (HOE901) and 3 more · For: Type 2 Diabetes Mellitus
Sites: Beijing, China; Cangzhou, China; Changchun, China · 79 sites in all
- GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of SulfonylureaPivotal-lookingCompleted
SanofiSanofi (SNY)
NCT00713830 · 859 participants · Start Jul 2008 · Primary completion Jan 2011
Drug: Lixisenatide (AVE0010); Placebo and 2 more · For: Diabetes Mellitus, Type 2
Sites: Bridgewater, New Jersey; Sofia, Bulgaria; Prague, Czechia · 16 sites in all
- Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination Versus Insulin Glargine in Patients With Type 2 DiabetesPivotal-lookingCompleted
SanofiSanofi (SNY)
NCT02058160 · 736 participants · Start Jan 2014 · Primary completion Jul 2015
Drug: Insulin glargine/lixisenatide (HOE901/AVE0010); Insulin glargine (HOE901) and 1 more · For: Type 2 Diabetes
Sites: Birmingham, Alabama; Sun City, Arizona; Tempe, Arizona · 236 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- GLP-1 therapies and hair loss: A systematic review of current evidence and implications for counseling.
Gupta AK, Teasell EM, Economopoulos V, et al. · Sci Prog 2026 · Systematic Review
- Trial of Lixisenatide in Early Parkinson's Disease.
Meissner WG, Remy P, Giordana C, et al. · N Engl J Med 2024 · Randomized Controlled Trial, Clinical Trial, Phase II
- Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.
Kristensen SL, Rørth R, Jhund PS, et al. · Lancet Diabetes Endocrinol 2019 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Cardiovascular Effects and Tolerability of GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis of 99,599 Patients.
Galli M, Benenati S, Laudani C, et al. · J Am Coll Cardiol 2025 · Systematic Review, Meta-Analysis
- Clinical Evidence for GLP-1 Receptor Agonists in Alzheimer's Disease: A Systematic Review.
Liang Y, Doré V, Rowe CC, et al. · J Alzheimers Dis Rep 2024 · Systematic Review
- Effects of Anti-Diabetic Drugs on Fracture Risk: A Systematic Review and Network Meta-Analysis.
Zhang YS, Zheng YD, Yuan Y, et al. · Front Endocrinol (Lausanne) 2021 · Research Support, Non-U.S. Gov't, Systematic Review
Sponsor: Sanofi
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.